About: TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine     Goto   Sponge   Distinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • TNF-related apoptosis-inducing ligand (TRAIL) is a proapoptotic cytokine implicated in cancer cell surveillance. Prolonged exposure of TRAIL-sensitive leukemia cell line HL60 cells to recombinant TRAIL or to cytostatic agents, cytarabine and idarubicin, resulted in the establishment of resistant subclones with distinct phenotypes. The TRAIL resistant subclones had decreased expression of TRAIL and TNFa death receptors, impaired activation of caspases 8 and 10 in response to TRAIL and TNFa and dysregulated expression of several apoptosis regulators. TRAIL resistant HL60 showed two phenotypes with different expression of CD14, osteoprotegerin, and several apoptosis regulators and were resistant to TNFa, suggesting disruption of the extrinsic apoptotic pathway. The concurrently derived cytarabine and idarubicin-resistant HL60 subclones remained sensitive to TRAIL-induced apoptosis. We identified distinct pathways for the development of HL60 leukemia cell resistance to apoptosis induction.
  • TNF-related apoptosis-inducing ligand (TRAIL) is a proapoptotic cytokine implicated in cancer cell surveillance. Prolonged exposure of TRAIL-sensitive leukemia cell line HL60 cells to recombinant TRAIL or to cytostatic agents, cytarabine and idarubicin, resulted in the establishment of resistant subclones with distinct phenotypes. The TRAIL resistant subclones had decreased expression of TRAIL and TNFa death receptors, impaired activation of caspases 8 and 10 in response to TRAIL and TNFa and dysregulated expression of several apoptosis regulators. TRAIL resistant HL60 showed two phenotypes with different expression of CD14, osteoprotegerin, and several apoptosis regulators and were resistant to TNFa, suggesting disruption of the extrinsic apoptotic pathway. The concurrently derived cytarabine and idarubicin-resistant HL60 subclones remained sensitive to TRAIL-induced apoptosis. We identified distinct pathways for the development of HL60 leukemia cell resistance to apoptosis induction. (en)
Title
  • TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine
  • TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine (en)
skos:prefLabel
  • TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine
  • TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine (en)
skos:notation
  • RIV/68378050:_____/09:00334040!RIV10-MSM-68378050
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • P(1M0506), P(LC06044), P(NR8317), S, Z(AV0Z50520514), Z(MSM0021620806), Z(MSM0021620808)
http://linked.open...iv/cisloPeriodika
  • 1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 346656
http://linked.open...ai/riv/idVysledku
  • RIV/68378050:_____/09:00334040
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • TRAIL resistance; leukemia; therapy (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • US - Spojené státy americké
http://linked.open...ontrolniKodProRIV
  • [7C5FF7CF4D5E]
http://linked.open...i/riv/nazevZdroje
  • Blood Cells Molecules and Diseases
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 42
http://linked.open...iv/tvurceVysledku
  • Anděra, Ladislav
  • Nečas, E.
  • Živný, J.
  • Čermák, J.
  • Klener, P. jr.
  • Leahomschi, S.
  • Molinsky, J.
  • Simonova, T.
  • Doležalová, L.
  • Gašová, Z.
http://linked.open...ain/vavai/riv/wos
  • 000262347900014
http://linked.open...n/vavai/riv/zamer
issn
  • 1079-9796
number of pages
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 85 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software